AC Immune (ACIU) Return on Capital Employed (2016 - 2025)
AC Immune (ACIU) reported Return on Capital Employed of 97.53% for Q4 2025, down 6009.0% year-over-year from 1.65% in Q4 2024, and down 12.04% on a QoQ basis from 87.05% in Q3 2025.
AC Immune (ACIU) has 9 years of Return on Capital Employed data on file, last reported at 97.53% in Q4 2025.
- Quarterly Return on Capital Employed fell 6009.0% year-over-year to 97.53% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 97.53% (down 6009.0% YoY) and the FY2025 annual result came in at 75.59%, down 2565.0% from the prior year.
- Return on Capital Employed fell to 97.53% in Q4 2025 per ACIU's latest filing, from 87.05% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 0.64% in Q1 2021 and bottomed at 97.53% in Q4 2025.
- The 5-year median for Return on Capital Employed is 38.73% (2022), against an average of 35.78%.
- The widest annual swing landed in 2023, when Return on Capital Employed jumped 3932 bps; it then slumped 6023 bps in 2025.
- Tracing ACIU's Return on Capital Employed over 5 years: stood at 0.4% in 2021, then slumped by 9824 bps to 38.93% in 2022, then jumped by 101 bps to 0.39% in 2023, then plunged by 9623 bps to 37.45% in 2024, then plunged by 160 bps to 97.53% in 2025.
- Per Business Quant, the three latest ACIU Return on Capital Employed figures stand at 97.53% (Q4 2025), 87.05% (Q3 2025), and 51.3% (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -97.53% |
| Sep 30, 2025 | -87.05% |
| Jun 30, 2025 | -51.30% |
| Mar 31, 2025 | -41.49% |
| Dec 31, 2024 | -37.45% |
| Sep 30, 2024 | -26.82% |
| Jun 30, 2024 | -58.34% |
| Mar 31, 2024 | -34.73% |
| Dec 31, 2023 | 0.39% |
| Sep 30, 2023 | -48.44% |
| Jun 30, 2023 | -42.98% |
| Mar 31, 2023 | -41.38% |
| Dec 31, 2022 | -38.93% |
| Sep 30, 2022 | -38.88% |
| Jun 30, 2022 | -38.57% |
| Mar 31, 2022 | -34.20% |
| Dec 31, 2021 | 0.40% |
| Sep 30, 2021 | 0.54% |
| Jun 30, 2021 | 0.63% |
| Mar 31, 2021 | 0.64% |
| Dec 31, 2020 | -25.71% |
| Sep 30, 2020 | -23.78% |
| Jun 30, 2020 | -8.87% |
| Mar 31, 2020 | -8.08% |
| Dec 31, 2019 | 15.33% |
| Sep 30, 2019 | 0.03% |
| Jun 30, 2019 | 0.01% |
| Mar 31, 2019 | 11.14% |
| Mar 31, 2017 | -5.62% |
| Dec 31, 2016 | -4.37% |